Yesterday was a great example of the total disconnect

New Post Public Reply Private Reply Replies (3) Message Board
Mo
891
Yesterday was a great example of the total disconnect between IPIX’s science value proposition and IPIX’s share price (SP). Signing a third MTA with “a leading U.S.-based Public Health Research Institute with access to a Biosafety Level-3 (BSL-3) laboratory” is very positive news as IPIX continues to advance Brilacidin as a treatment and possible adjuvant for a vaccine for COVID-19. Testing will include evaluating Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus. IMO this age dependent testing indicates a primary interest to use Brilacidin as a critical adjuvant for a vaccine for this specific MTA.

Separately, testing started at the RBL over the weekend on human lung cells and a successful conclusion to this testing will move Brilacidin to the top of the treatment list and accelerate Brilacidin through phase 3 trials.

So what happened to the SP on this great news? It closed down a tenth of a penny on over 2.7M shares. Is there really as much supply of sellers at 17 cents as there is demand to buy at 17 cents? Anyone with half a brain knows this is bullshit. Let’s start with a reminder of last September’s Shareholder Meeting with a 90% vote FOR expanding Authorized Shares. This is a proof point that Long Term Shareholders have faith in the direction and science advancement of IPIX. Note that since September IPIX’s true value has tremendously increased with a successful B-IBD Oral Phase I using the BDD technology advancing Brilacidin closer to being a major player in a $48B IBD market. Also note that COVID-19 didn’t even exist in September and Brilacidin has not only received valuable free testing but is a top contender as a COVID-19 treatment. The point is that if IPIX Investors continue to strongly support the company and know that IPIX SP is greatly undervalued, then who in their right mind would be selling shares at these levels?

The soft bashers will point to the MFO selling shares which might account for a very small percentage of volume but the math does not simply add up. Leo has dropped expenses down to around $600k/month and currently is very busy getting free research and testing done with numerous entities. If you look at the tape of trades there is an obvious abundance of mirror trades or wash transactions where it is very obvious that volume is artificially inflated (fake).

Any storyline that talks about where we are today as IPIX investors should include 2 major issues. #1 is the great job IPIX has done to advance the science against severe head winds. #2 is the criminal abuse against IPIX and the continual compression of IPIX SP. The soft bashers will post statements like “Gee I wonder why IPIX SP is so low?” Much of the following has been discussed many times and I recently PMed some of this info to a newbie.

Criminal Naked Short Selling (NSS) is a hard concept to understand. If you look at the criminal or Non Retail (NR) pyramid there are the hard bashers on the bottom which are low paid and low knowledge idiots. As you move up the criminal chain there are paid soft bashers that are skilled to be pretend longs and create false narratives and spread FUD. Further up the chain there are trading gangs that are funded by the top of the chain. The next ladder up is crooked Market Makers that not only fill the NSS orders but do daily mirror or wash trades to make the appearance of volume that is mostly fake and do much of the dirty work to compress SP. Towards the top is a hedge fund that is the money behind the entire criminal activity. There may or may not be an entity that is above the hedge fund directing activity.

The logical question is why attack IPIX when it sells for pennies? Legal shorts would not mess around with a 16 cent share company. They would be long gone and off to attack a target with more meat on the bone that has less upside. Naked Short Selling (NSS) however is completely different in that shares are not borrowed which is illegal. NSS has a completely different goal than legal short sellers do. The answer is that the criminals/NR compress the SP of many small start-up, pre-revenue companies on the OTX that need to issue stock to keep the lights on. Baby biotech is an easy target as it takes 10 years on average to get a drug from lab to market. With little or no revenue coming in, their only method of advancing their science is to issue stock. (dilution). The criminals/NR goal is not to simply lower the share price (SP) but it is to PUT THEIR TARGET OUT OF BUSINESS. If their target dilutes to a point where they never get a product/drug to market and their SP goes to zero, the criminals NEVER have to cover their naked position. NR has never legally borrowed IPIX shares to legally short. NR DOES NOT have actual IPIX shares. NR needs REAL INVESTORS TO SELL THEM REAL SHARES. They have illegally shorted a stock WITHOUT borrowing the shares. The SEC pays little attention to abuse on the OTX based companies. 90% of NR's targets go belly up and the criminals (hedge fund and all above) make many millions. BUT maybe 1 out of 10 of these targeted companies do indeed survive. Most of those 10% are heavily diluted if they do survive.

IPIX's CEO Leo Ehrlich however has been very frugal to slowly advance IPIX science and has avoided heavy OS dilution (less than 270M shares) or taking on toxic debt. IMO NR will continue to control IPIX SP until it is in the dollars per share. Once funding becomes a non-issue and Brilacidin makes it through phase 3 and starts to produce revenue, NR will START to lose control of SP. A $3 to $5 SP IMO will only be the START of a huge run over the next few years. Some Long term investors will start selling a PORTION of their holdings once IPIX SP is into several dollars per share at which point NR will SLOWLY have to buy ACTUAL shares to cover their naked position. If NR tried for example to cover their naked position starting with flippers and some Longs at say $2 or $3/share the SP would explode upward due to lack of supply.

IMO an investment in IPIX should be focused on MILESTONES and not short term share price or volume which are both currently controlled by NR and therefore are both fake. This control will change as milestones are met with science advancement, grant funding, royalty revenue, up-listing, partnerships and at some point in the future the sale of the company. These milestone achievements will not only lift IPIX’s SP but will also neutralize NR’s control as new investors flood to IPIX producing demand. Do not go for the head fake as IPIX SP spikes up in the sub dollar range. A real short squeeze will be in dollar multiples over a few days when it eventually takes place. IMO IPIX investors are in for a very unique, wealth building ride as IPIX science improves and saves lives.


1

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Health Net Invests $3 Million in Stockton Housing

Updated Category News Views 145

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Continue Reading
Partner Joins Yardi ICN, Boosting Data Quality for Clients

Updated Category News Views 91

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

Continue Reading
Dyania, NVIDIA Team Up: AI Transforming Patient Care

Updated Category News Views 61

Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...

Continue Reading
D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Updated Category News Views 101

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...

Continue Reading
Euroandinos Paita Closes Consent for 2037 Notes

Updated Category News Views 70

Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...

Continue Reading
PenFed Fuels Aggie Spirit with Blackout Game Activation

Updated Category News Views 156

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 46

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Fly-E Faces Revenue Drop Amid Retail Restructuring

Updated Category News Views 215

Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
FiEE Rockets to Profitability with 382% Revenue Surge

Updated Category News Views 170

Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...

Continue Reading

Top 5 Most Recently Viewed Articles

Alta Equipment Group's Dividend Declaration and Company Overview

Updated Category News Views 52

Recent Dividend Announcement from Alta Equipment Group Alta Equipment Group Inc. (NYSE: ALTG), a prominent player in premium material handling and construction equipment, has recently made headlines with the announcement of its latest quarterly dividend. The Board of Directors has sanctioned a dividend amounting to $0.057 per share for its common stock, reflecting the...

Continue Reading
I Peace Unveils Innovative iPSC Lines for Better Therapy Access

Updated Category News Views 331

I Peace Introduces New iPSC Lines to Enhance Cell Therapy Leading the way in regenerative medicine, I Peace, Inc. has proudly announced the development of new induced pluripotent stem cell (iPSC) lines that aim to significantly reduce the risk of immune rejection among patients. This groundbreaking innovation is particularly relevant for the U.S. population, where over...

Continue Reading
Vendasta Welcomes New Board Members for AI Innovation

Updated Category News Views 189

Vendasta Strengthens Leadership with New Board Appointments Vendasta has made significant strides recently by welcoming two prominent figures to its Board of Directors. The company, renowned for its innovative AI solutions for small businesses, is excited to onboard Eric Johnson, formerly CEO of SurveyMonkey, and Brent Remai, the long-serving CMO of Cloudflare. Their...

Continue Reading
DICK'S Sporting Goods Expands Offer with Foot Locker Notes Exchange

Updated Category News Views 166

DICK'S Sporting Goods Moves Forward in Foot Locker Notes Exchange DICK'S Sporting Goods, Inc. (NYSE: DKS), a prominent U.S.-based retailer specializing in sporting goods, has made a key announcement regarding an exchange offer for Foot Locker, Inc.'s outstanding notes. This exchange is part of DICK'S broader strategy to enhance its financial flexibility and grow its...

Continue Reading
Northwell Health Unveils Institute of Translational Research

Updated Category News Views 195

Northwell Health Launches New Institute for Research Northwell Health, a leader in medical research, has announced the establishment of its sixth research institute, now known as the Institute of Translational Research. This new institute intends to bridge the gap between basic molecular mechanisms of chronic diseases and the development of innovative clinical therapies....

Continue Reading